Skip to main content

Table 1 Intensive front-line therapy for young fit patient with mantle cell lymphoma (MCL)

From: Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Regimen Series No. Age(ys) Median (range) MIPI Low/Int/High(%) ORR (%) CR (%) mFU (ms) mPFS (ms) mOS (ms) TRM (%) Second malignancy(%)
R-hyper-CVAD/R-MA Chihara (2016) [7, 27] 65 56(41–65) 5.52(4.87–6.91) Score 97 (of 97 cases) 89 13.4 ys 6.5 ys 13.4 ys 6.5 26
R-hyper-CVAD/R-MA Merli (2012) [24] 60 57(29–66) 60/31/9 83 72 46 61% (5-y PFS) 73% (5-y OS) 5 1.6
CHOP-Like + interferon-α
VS.
CHOP-Like + ASCT
Dreyling(2005) [21] 60 55(37–65) 42/54/4 (IPI) 99 Vs 98 37 Vs. 81 34 17 3-y OS, 77% 0 na
62 56(35–65) 44/49/7(IPI) 39 3-y OS, 83% 5 na
R-CHOP+ASCT
Vs.
R-CHOP/R-DHAP + HD-Ara-c + ASCT
Hermine (2012) [31, 32] 234 55 (48–60) 60/26/14 97. Vs 97 63 Vs. 65 6.1ys 3.9 ysa 5-y OS, 40% 3.4 5.2
232 56 (50–60) 65/22/13 9.1 ysa 5-y OS, 65% 3.4 6.7
R-CHOP + MTX + R + HD-AraC/etoposide + ASCT Damon (2009) [63] 78 57 (37–69) 53/31/15 (1 Unknown) 88 69 4.7ys 56% (5-y PFS) 64% (5-y OS) 2.6 na
R-CHOP + HD-Ara-c + ASCT Van’t Veer (2008) [64] 87 55 (32–66) 51/29/20 70 64 41.7 44% (4-y PFS) 66% (4-y OS) 6.9 na
R-CHOP/R-DHAP + HD-Ara-c + ASCT Delarue,2013 [33] 60 57 (40–66) 55/32/13 82 78 5.6ys 64% (5-y EFS) 75% (5-y OS) 1.7 18
R-DHAP + ASCT Le Gouill (2014) [65] 299 57 (27–65) 53.2/27.4/19.4 na 92 35.8 74% (3-y PFS) 83% (3-y OS) na na
R-CHOP+R-CTX + R-HD-Ara-c + ASCT +/− LEN Cortelazzo(2015) [54] 266 57 (51–61) Int-High:53 86 77 19 77% (2-y PFS) 88% (2-y OS) 1.6 na
R-maxi-CHOPb/HD-Ara-c + ASCT +/− R Eskelund (2016) [9] 159 56 (32–65) 51/26/23 96 89.7 11.4ys 8.5ys 12.7ys 7 12.6
R-CHOP-14 + (R)ICE +ASCT Schaffel (2010) [66] 69 < 60, 71%
≥60, 29%
19/49/32 na na 4.8ys 65% (4-y PFS) 84% (4-y OS) 1 na
  1. Abbreviations: HD-Ara-c high-dose cytarabine, ASCT autologous stem-cell transplantation, R rituximab, CR complete response, MIPI mantle cell lymphoma-international prognostic index, Int intermediate, mFU Median follow-up, mPFS median progression-free survival, EFS event-free survival, mOS median overall survival, ORR overall response rate, TRM treatment-related mortality; a TTF time to treatment failure
  2. NR not reached, na not available, ne not evaluable, ms months, ys years, vs. versus
  3. hyper-CVAD/MA, fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate-cytarabine;
  4. DHAP, dexamethasone, cytarabine, carboplatin or cisplatin; bmaxi-CHOP: cyclophosphamide 1200 mg/m 2, doxorubicin 75 mg/m 2, vincristine 2 mg total day1;prednisone 100 mg days1–5; LEN: lenalidomide; ICE, ifosfamide, carboplatin, and etoposide